Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

Abstract Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Supavit Chesdachai, Christina G. Rivera, Kristin C. Cole, Hilary R. Teaford, Maria L. Gonzalez Suarez, Jennifer J. Larsen, Ravindra Ganesh, Sidna Tulledge-Scheitel, Raymund R. Razonable
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2024-03-01
Saila:	Scientific Reports
Gaiak:	COVID-19 Outcome Remdesivir SARS-2-CoV Sotrovimab
Sarrera elektronikoa:	https://doi.org/10.1038/s41598-024-56195-y
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!